Circulating bone morphogenetic protein 10 as a novel marker of atrial stress and remodelling in heart failure.

Background: We evaluated the potential of circulating bone morphogenetic protein 10 (BMP10) as a biomarker for atrial stress and remodelling in patients with heart failure (HF), in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP). We also assessed the predictive value of BMP10 for adverse clinical outcomes.

Methods: BMP10 levels were quantified in 2085 chronic HF patients from the European BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) cohort and in 1487 patients from the Scottish validation cohort.

Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure.

Aims: Elevated concentrations of growth differentiation factor 15 (GDF-15) in patients with heart failure (HF) have been consistently associated with worse clinical outcomes, but what disease mechanisms high GDF-15 concentrations represent remains unclear. Here, we aim to identify activated pathophysiological pathways related to elevated GDF-15 expression in patients with HF.

Methods And Results: In 2279 patients with HF, we measured circulating levels of 363 biomarkers.

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction.

Aims: The lack of effective therapies for patients with heart failure with preserved ejection fraction (HFpEF) is often ascribed to the heterogeneity of patients with HFpEF. We aimed to identify distinct pathophysiologic clusters of HFpEF based on circulating biomarkers.

Methods And Results: We performed an unsupervised cluster analysis using 363 biomarkers from 429 patients with HFpEF.